{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-274491","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.065923+00:00","generated_at":"2026-06-22T19:32:02.348508+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Johnson & Johnson to acquire Abiomed for $380/share plus CVR; enterprise value ~$16.6B","bullets":["Upfront cash $380/share + CVR up to $35/share; total implied value ~$415/share.","Enterprise value ~$16.6B including cash acquired; deal expected to close by mid-2023.","CVR milestones: net sales >$3.7B; FDA approval for Impella in STEMI; Class I guidelines.","Transaction broadens JNJ MedTech cardiovascular portfolio; accretive to adjusted EPS in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-274491","json":"https://secwatch.observer/filing/0001193125-22-274491.json","markdown":"https://secwatch.observer/filing/0001193125-22-274491.md","text":"https://secwatch.observer/filing/0001193125-22-274491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/0001193125-22-274491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:32:02.348508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ef6c9faa42df9df96ce5d1baf9d257aa3e1746a","claim":"JOHNSON & JOHNSON entered into Agreement and Plan of Merger with ABIOMED, Inc. valued at Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on (effective 2022-10-31).","evidence_excerpt":"Item 1.01 Entry into a Material Definitive Agreement Agreement and Plan of Merger On October 31, 2022, Johnson & Johnson, a New Jersey corporation (“ Johnson & Johnson ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson (“ Merger Sub ”), and ABIOMED, Inc., a Delaware corporation (“ ABIOMED ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/0001193125-22-274491-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"ABIOMED, Inc."},{"label":"Value","value":"Johnson & Johnson to acquire all outstanding shares of ABIOMED for $380.00 per share in cash plus on"},{"label":"Effective","value":"2022-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}